{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:50:32Z","timestamp":1791049832908,"version":"4.1.0"},"reference-count":68,"publisher":"Japanese Society for the Study of Xenobiotics","issue":"5","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2006]]},"DOI":"10.2133\/dmpk.21.347","type":"journal-article","created":{"date-parts":[[2006,10,30]],"date-time":"2006-10-30T05:46:46Z","timestamp":1162187206000},"page":"347-356","source":"Crossref","is-referenced-by-count":119,"title":["Metabolic and Non-Metabolic Factors Determining Troglitazone Hepatotoxicity: A Review"],"prefix":"10.2133","volume":"21","author":[{"given":"Yasuhiro","family":"Masubuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"900","reference":[{"key":"10.2133\/dmpk.21.347_bb0005","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1056\/NEJM199803263381314","article-title":"Hepatic dysfunction associated with troglitazone","volume":"338","author":"Watkins","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.2133\/dmpk.21.347_bb0010","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/S0140-6736(00)04960-6","article-title":"Lessons from the glitazones: a story of drug development","volume":"357","author":"Gale","year":"2001","journal-title":"Lancet"},{"key":"10.2133\/dmpk.21.347_bb0015","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0002-9343(02)01529-2","article-title":"Troglitazone-induced liver failure: a case study","volume":"114","author":"Graham","year":"2003","journal-title":"Am. J. Med."},{"key":"10.2133\/dmpk.21.347_bb0020","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/jhep.2001.23505","article-title":"Drug-induced liver injury: mechanisms and test systems","volume":"33","author":"Bissell","year":"2001","journal-title":"Hepatology"},{"key":"10.2133\/dmpk.21.347_bb0025","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1021\/tx034033e","article-title":"Mechanisms of troglitazone hepatotoxicity","volume":"16","author":"Smith","year":"2003","journal-title":"Chem. Res. Toxicol."},{"key":"10.2133\/dmpk.21.347_bb0030","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/hep.20567","article-title":"Troglitazone and liver injury: in search of answers","volume":"41","author":"Chojkier","year":"2005","journal-title":"Hepatology"},{"key":"10.2133\/dmpk.21.347_bb0035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev.pharmtox.45.120403.100058","article-title":"The role of metabolic activation in drug-induced hepatotoxicity","volume":"45","author":"Park","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.2133\/dmpk.21.347_bb0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00003088-199937020-00001","article-title":"Clinical pharmacokinetics of troglitazone","volume":"37","author":"Loi","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"10.2133\/dmpk.21.347_bb0045","first-page":"356","article-title":"Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs","volume":"47","author":"Kawai","year":"1997","journal-title":"Arzneimittelforschung"},{"key":"10.2133\/dmpk.21.347_bb0050","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1124\/dmd.30.8.944","article-title":"Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver","volume":"30","author":"Honma","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.21.347_bb0055","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2131\/jts.25.5_433","article-title":"Characterization of UDP-glucuronosyltransferases (UGTs) involved in the metabolism of troglitazone in rats and humans","volume":"25","author":"Yoshigae","year":"2000","journal-title":"J. Toxicol. Sci."},{"key":"10.2133\/dmpk.21.347_bb0060","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1124\/dmd.30.12.1462","article-title":"Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10","volume":"30","author":"Watanabe","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.21.347_bb0065","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1021\/tx0001981","article-title":"Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo","volume":"14","author":"Tettey","year":"2001","journal-title":"Chem. Res. Toxicol"},{"key":"10.2133\/dmpk.21.347_bb0070","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0090-9556(24)14927-6","article-title":"Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes","volume":"27","author":"Yamazaki","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.21.347_bb0075","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0006-2952(01)00653-0","article-title":"Troglitazone quinone formation catalyzed by human and rat CYP3A: an atypical CYP oxidation reaction","volume":"62","author":"He","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.2133\/dmpk.21.347_bb0080","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1021\/tx000180q","article-title":"Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission","volume":"14","author":"Kassahun","year":"2001","journal-title":"Chem. Res. Toxicol"},{"key":"10.2133\/dmpk.21.347_bb0085","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S0090-9556(24)15045-3","article-title":"Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes","volume":"27","author":"Ramachandran","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.21.347_bb0090","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/004982500237668","article-title":"Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes","volume":"30","author":"Sahi","year":"2000","journal-title":"Xenobiotica"},{"key":"10.2133\/dmpk.21.347_bb0095","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0009-2797(02)00056-X","article-title":"Identification of glutathione conjugates of troglitazone in human hepatocytes","volume":"142","author":"Prabhu","year":"2002","journal-title":"Chem. Biol. Interact."},{"key":"10.2133\/dmpk.21.347_bb0100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/dmd.30.2.155","article-title":"Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells","volume":"30","author":"Yamamoto","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.21.347_bb0105","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1124\/dmd.104.003475","article-title":"Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6 and CYP1A2 in pooled human liver microsomes","volume":"33","author":"Lim","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.21.347_bb0110","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1124\/dmd.32.6.639","article-title":"Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved","volume":"32","author":"He","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.21.347_bb0115","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/S0024-3205(01)00985-7","article-title":"Toxic effect of troglitazone on cultured rat hepatocytes","volume":"68","author":"Toyoda","year":"2001","journal-title":"Life Sci."},{"key":"10.2133\/dmpk.21.347_bb0120","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s002040100251","article-title":"Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes","volume":"75","author":"Haskins","year":"2001","journal-title":"Arch. Toxicol."},{"key":"10.2133\/dmpk.21.347_bb0125","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0024-3205(01)01432-1","article-title":"Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells","volume":"70","author":"Yamamoto","year":"2001","journal-title":"Life Sci."},{"key":"10.2133\/dmpk.21.347_bb0130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0009-2797(02)00055-8","article-title":"Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes","volume":"142","author":"Hewitt","year":"2002","journal-title":"Chem. Biol. Interact."},{"key":"10.2133\/dmpk.21.347_bb0135","first-page":"1192","article-title":"The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures","volume":"28","author":"Kostrubsky","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.21.347_bb0140","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/toxsci\/69.1.131","article-title":"Effects of troglitazone on HepG2 viability and mitochondrial function","volume":"69","author":"Tirmenstein","year":"2002","journal-title":"Toxicol. Sci."},{"key":"10.2133\/dmpk.21.347_bb0145","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.tox.2005.08.003","article-title":"An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics","volume":"216","author":"Vignati","year":"2005","journal-title":"Toxicology"},{"key":"10.2133\/dmpk.21.347_bb0150","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/cyto.a.10011","article-title":"Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: a flow cytometric assessment","volume":"52A","author":"Narayanan","year":"2003","journal-title":"Cytometry"},{"issue":"vi","key":"10.2133\/dmpk.21.347_bb0155","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1089-3261(03)00020-5","article-title":"Hepatotoxicity of the thiazolidinediones","volume":"7","author":"Tolman","year":"2003","journal-title":"Clin. Liver Dis."},{"key":"10.2133\/dmpk.21.347_bb0160","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1517\/14740338.2.6.581","article-title":"Hepatotoxicity of thiazolidinediones","volume":"2","author":"Isley","year":"2003","journal-title":"Expert Opin. Drug Saf."},{"key":"10.2133\/dmpk.21.347_bb0165","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0009-2797(02)00054-6","article-title":"Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors","volume":"142","author":"Lloyd","year":"2002","journal-title":"Chem. Biol. Interact."},{"key":"10.2133\/dmpk.21.347_bb0170","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.tiv.2004.01.012","article-title":"Identification of in vitro protein biomarkers of idiosyncratic liver toxicity","volume":"18","author":"Gao","year":"2004","journal-title":"Toxicol. In Vitro"},{"key":"10.2133\/dmpk.21.347_bb0175","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpba.2004.04.019","article-title":"The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent","volume":"36","author":"Soglia","year":"2004","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.2133\/dmpk.21.347_bb0180","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1124\/dmd.104.002683","article-title":"Metabolic activation of pioglitazone identified from rat and human liver microsomes and freshly isolated hepatocytes","volume":"33","author":"Baughman","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.21.347_bb0185","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/mol.63.2.401","article-title":"Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells","volume":"63","author":"Bae","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.2133\/dmpk.21.347_bb0190","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0378-4274(02)00468-X","article-title":"Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines","volume":"139","author":"Bae","year":"2003","journal-title":"Toxicol. Lett."},{"key":"10.2133\/dmpk.21.347_bb0195","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mrfmmm.2003.11.015","article-title":"Applications of microarrays with toxicologically relevant genes (tox genes) for the evaluation of chemical toxicants in Sprague Dawley rats in vivo and human hepatocytes in vitro","volume":"549","author":"Kier","year":"2004","journal-title":"Mutat. Res."},{"key":"10.2133\/dmpk.21.347_bb0200","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/toxsci\/kfi022","article-title":"Chaperone proteins involved in troglitazone-induced toxicity in human hepatoma cell lines","volume":"83","author":"Maniratanachote","year":"2005","journal-title":"Toxicol. Sci."},{"key":"10.2133\/dmpk.21.347_bb0205","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0009-9236(03)00014-6","article-title":"A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus","volume":"73","author":"Watanabe","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.21.347_bb0210","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/jhep.2003.50014","article-title":"Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes","volume":"37","author":"Shishido","year":"2003","journal-title":"Hepatology"},{"key":"10.2133\/dmpk.21.347_bb0215","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.toxlet.2004.08.009","article-title":"Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells","volume":"155","author":"Bova","year":"2005","journal-title":"Toxicol. Lett."},{"key":"10.2133\/dmpk.21.347_bb0220","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0005-2728(96)00041-2","article-title":"The permeability transition pore. Control points of a cyclosporin A-sensitive mitochondrial channel involved in cell death","volume":"1275","author":"Bernardi","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"10.2133\/dmpk.21.347_bb0225","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0005-2728(98)00112-1","article-title":"The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy","volume":"1366","author":"Lemasters","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.2133\/dmpk.21.347_bb0230","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1053\/jhep.2002.31871","article-title":"Role of mitochondrial permeability transition in diclofenacinduced hepatocyte injury in rats","volume":"35","author":"Masubuchi","year":"2002","journal-title":"Hepatology"},{"key":"10.2133\/dmpk.21.347_bb0235","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jhep.2004.09.015","article-title":"Involvement of mitochondrial permeability transition in acetaminopheninduced liver injury in mice","volume":"42","author":"Masubuchi","year":"2005","journal-title":"J. Hepatol."},{"key":"10.2133\/dmpk.21.347_bb0240","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.tox.2006.02.017","article-title":"Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones","volume":"222","author":"Masubuchi","year":"2006","journal-title":"Toxicology"},{"key":"10.2133\/dmpk.21.347_bb0245","first-page":"1835","article-title":"Intracellular ATP levels determine cell death fate by apoptosis or necrosis","volume":"57","author":"Eguchi","year":"1997","journal-title":"Cancer Res."},{"key":"10.2133\/dmpk.21.347_bb0250","first-page":"G1","article-title":"Mechanisms of Hepatic Toxicity. V. Necrapoptosis and the mitochondrial permeability transition: shared pathways to necrosis and apoptosis","volume":"276","author":"Lemasters","year":"1999","journal-title":"Am. J. Physiol."},{"key":"10.2133\/dmpk.21.347_bb0255","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/0008-5472.CAN-04-1677","article-title":"Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL\/BBcl-2 functions independently of PPAR\u03b3","volume":"65","author":"Shiau","year":"2005","journal-title":"Cancer Res."},{"key":"10.2133\/dmpk.21.347_bb0260","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/hep.20994","article-title":"Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo","volume":"43","author":"Yu","year":"2006","journal-title":"Hepatology"},{"key":"10.2133\/dmpk.21.347_bb0265","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s002100000352","article-title":"Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway","volume":"363","author":"Gouni-Berthold","year":"2001","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."},{"key":"10.2133\/dmpk.21.347_bb0270","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0027-5107(95)00136-0","article-title":"PPAR: a mediator of peroxisome proliferator action","volume":"333","author":"Green","year":"1995","journal-title":"Mutat. Res."},{"key":"10.2133\/dmpk.21.347_bb0275","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0168-8278(01)00066-6","article-title":"Diabetic KKAy mice exhibit increased hepatic PPAR\u03b31 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones","volume":"35","author":"Bedoucha","year":"2001","journal-title":"J. Hepatol."},{"key":"10.2133\/dmpk.21.347_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-2952(01)00817-6","article-title":"Toxicological consequences of altered peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) expression in the liver: insights from models of obesity and type 2 diabetes","volume":"63","author":"Boelsterli","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"10.2133\/dmpk.21.347_bb0285","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.hepres.2005.09.027","article-title":"Thiazolidinediones: Pleiotropic drugs with potent anti-inflammatory properties for tissue protection","volume":"33","author":"Buckingham","year":"2005","journal-title":"Hepatol. Res."},{"key":"10.2133\/dmpk.21.347_bb0290","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1124\/jpet.102.047217","article-title":"Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-\u03b3, pioglitazone","volume":"306","author":"Enomoto","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.2133\/dmpk.21.347_bb0295","doi-asserted-by":"crossref","first-page":"139S","DOI":"10.1097\/01.ALC.0000134412.38510.F7","article-title":"Pioglitazone prevents acute liver injury induced by ethanol and lipopolysaccharide through the suppression of tumor necrosis factor-alpha","volume":"28","author":"Ohata","year":"2004","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.2133\/dmpk.21.347_bb0300","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1053\/j.gastro.2003.12.008","article-title":"Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met","volume":"126","author":"Tomita","year":"2004","journal-title":"Gastroenterology"},{"key":"10.2133\/dmpk.21.347_bb0305","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0006-2952(00)00299-9","article-title":"Downregulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes","volume":"60","author":"Sigrist","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.2133\/dmpk.21.347_bb0310","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/hep.510310123","article-title":"Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice","volume":"31","author":"Kovalovich","year":"2000","journal-title":"Hepatology"},{"key":"10.2133\/dmpk.21.347_bb0315","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0006-291X(03)00572-2","article-title":"Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease","volume":"304","author":"Masubuchi","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.2133\/dmpk.21.347_bb0320","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/sj.bjp.0702318","article-title":"Acute troglitazone action in isolated perfused rat liver","volume":"126","author":"Preininger","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.2133\/dmpk.21.347_bb0325","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/mol.59.3.627","article-title":"Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat","volume":"59","author":"Funk","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.2133\/dmpk.21.347_bb0330","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0300-483X(01)00460-7","volume":"167","author":"Funk","year":"2001","journal-title":"Toxicology"},{"key":"10.2133\/dmpk.21.347_bb0335","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1124\/dmd.32.3.291","article-title":"Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity","volume":"32","author":"Nozawa","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.21.347_bb0340","first-page":"1561","article-title":"The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter-deficient rats","volume":"29","author":"Kostrubsky","year":"2001","journal-title":"Drug Metab. Dispos."}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715307060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715307060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T18:40:20Z","timestamp":1736620820000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436715307060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006]]}},"alternative-id":["S1347436715307060"],"URL":"https:\/\/doi.org\/10.2133\/dmpk.21.347","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2006]]}}}